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Dear Editor 
Granulocyte - macrophage colony stimulating factor 
and bronchial asthma - A hypothesis for novel 
therapeutic options 
Current concepts of the pathogenesis of bronchial 
asthma indicate an inflammatory model (1). In this 
context, modulation of peripheral and airway 
eosinophils should play a role in the pathophysiology 
of asthma (1). Similarly, neutrophils are also impli- 
cated and neutrophil depletion ablates late phase 
response in bronchial asthma (2). Granulocyte - 
macrophage colony stimulating factor (GM-CSF) 
stimulates production of neutrophils, eosinophils and 
monocytes of peripheral blood and bone marrow (1). 
Recent studies from Japan have shown increased 
GM-CSF production by mononuclear cells from the 
peripheral blood of patients with bronchial asthma 
(1). The same study also stressed the importance of 
GM-CSF in the proliferation and survival of inflam- 
matory cells in bronchial asthmatics. The acquisition 
of bronchial asthma by recipients of bone marrow 
from donors with clinically symptomatic asthma, 
following bone marrow transplantation has been 
reported previously (3). 
The findings that bronchial asthma can be trans- 
mitted by bone marrow transplantation and that 
GM-CSF production is increased in the peripheral 
blood of bronchial asthmatics should have important 
implications; as logically, neutrophil and eosinophil 
depletion should reduce the inflammatory compo- 
nent of bronchial asthma. Depletion of neutrophils 
abolishes bronchial hyper-responsiveness in dogs and 
rabbits (4). Corticosteroids are effective in the treat- 
ment of bronchial asthma and they are known to 
produce eosinopenia (5). Do these findings suggest a 
role for GM-CSF in asthmatics? It has been hypoth- 
esized that the haemopoietic growth factors (e.g. 
GM-CSF) and drugs such as gold salts and chloro- 
quine have opposing actions in the proliferation of 
bone marrow myeloid progenitors in rheumatoid 
arthritis, producing leucopenia and hence decreased 
inflammatory response (6). Methotrexate inhibits 
myeloid colony formation in vitro (6). It is interesting 
to note that drugs such as gold salts, hydroxy- 
chloroquine and methotrexate are also used in the 
treatment of bronchial asthma (2). Hence, the oppos- 
ing effects of GM-CSF and gold salts, hydroxy- 
chloroquine and methotrexate on the bone marrow 
precursor cells should be true in bronchial asthmatics 
as well. 
Corticosteroids act in asthmatics by their effect on 
GM-CSF by inhibiting GM-CSF at the transcription 
level, by inhibiting GM-CSF’s permissive action on 
eosinophil survival and also by decreasing eosinophil 
production in bone marrow (5). The blocking effects 
of antibodies of GM-CSF on eosinophils in bronchial 
asthmatics has been demonstrated (1). Does this 
suggest the opening of a novel direction in bronchial 
asthma therapy? There is a need for further studies in 
asthmatics with drugs presumed to have opposing 
effects on GM-CSF. 
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Kasturba Medical College Hospital 
Manipal, India 
10 May 1995 
References 
1. Youichi N, Toshio 0, Toshihiko K et al. Increased 
granulocyte/macrophage colony stimulating factor pro- 
duction by mononuclear cells from peripheral blood of 
patients with bronchial asthma. Am Rev Resoir Dis 1993: 
i47: 87-91. 
2. Bruce AB, Myron IL, Zeb D et al. The effect of dapsone 
in steroid dependent asthma. J Allergy Clin Immunol 
1991; 87: 71&714. 
3. Jan MA, Jay DS, Lawrence GL ef al. Transfer of 
allergen specific IgE - mediated hypersensitivity with 
allergenic bone marrow transplantation. N. Engl J Med 
1988; 319: 1623-1627. 
4. Clark Lantz R, Richard D. Immunologically mediated 
lung diseases. In: Daniel EB, ed. Immunology and Allergy 
Clinics of North America. Philadelphia: W. B. Saunders 
Company, 1992; 12 (2): 3077321. 
5. Peter JB, Soren P. Efficacy and safety of inhaled corti- 
costeroids in asthma. Am Rev Respir Dis 1993; 148: 
Sl-S26. 
6. Hamilton JA. Rheumatoid arthritis: opposing actions 
of haemopoietic growth factors and slow-acting 
anti-rheumatic drugs. Lancet 1993; 342: 536538. 
Dear Editor 
Idiopathic pulmonary haemosiderosis (IPH) 
We read with interest the case reported by Bouros 
et al. (l), as we reported a similar case of IPH in a 
young male (2). Our patient was an ‘occasional’ 
smoker whose mother kept a meticulous diary detail- 
ing her son’s smoking habits. He had relapses and on 
each occasion he had commenced smoking about 6 
weeks previously. Twelve years after initial presenta- 
tion, 10 years after stopping smoking and 9 years 
since corticosteroids were stopped, he remains 
clinically fit and healthy. 
Tobacco smoke has a profound effect both in vitro 
and in vivo on immune function. We suggested the 
possibility that smoking may have contributed to 
these relapses and advised that it would be wise to 
